Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network.
Surveillance de la santé et des maladies
Public Access
Published
Auteurs
Angela M Rose [2]; Francisco Pozo [3]; Iván Martínez-Baz [4]; Clara Mazagatos [5]; Nathalie Bossuyt [6]; John Paul Cauchi [7]; Petrović, Goranka [8]; Isabela I Loghin [9]; Roberta Vaikutyte [10]; Silke Buda [11]; Machado, Ausenda [12]; Róisín Duffy [13]; Beatrix Oroszi [14]; Howard, Jennifer [15]; Echeverria, Aitziber [16]; Cristina Andreu [17]; Cyril Barbezange [18]; Aušra Džiugytė [19]; Diana Nonković [20]; Popescu, Corneliu-Petru [21]; Fausta Majauskaite [22]; Kristin Tolksdorf [23]; Verónica Gomez [24]; Domegan, Lisa [25]; Judit Krisztina Horváth [26]; Jesús Castilla [27]; Miriam García [28]; Thomas Demuyser [29]; Maria-Louise Borg [30]; Irena Tabain [31]; Mihaela Lazar [32]; Ieva Kubiliute [33]; Ralf Dürrwald [34]; Raquel Guiomar [35]; O'Donnell, Joan [36]; Kristóf, Katalin [37]; Nathalie Nicolay [38]; Sabrina Bacci [39]; Kissling, Esther [40]Mots-clés
Article written during project(s) :
Résumé:
We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: -23-36); 20% (95% CI: -4-39) against A(H3N2) and 56% (95% CI: 22-75) against B. During the 2022/2023 season, while VE against hospitalisation with influenza B was >55%, it was ≤20% for influenza…